Kedrion S.p.a.
Clinical trials sponsored by Kedrion S.p.a., explained in plain language.
-
New hope for rare bleeding disorder: drug trial targets Life-Threatening clot deficiency
Disease control Recruiting nowThis study tests a drug called Coagadex to see if it can safely stop or prevent bleeding in adults with a rare condition where their blood doesn't clot properly. The condition is caused by a disease called AL amyloidosis. About 15 people aged 18 to 70 will receive the drug and be…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
New study aims to find best dose of immune therapy for nerve disorder
Disease control Recruiting nowThis study tests two different doses of a medicine called KIg10 (a type of immune globulin given through a vein) to see which works better as a long-term treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve condition that causes weakness and…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New hope for chronic ITP patients: phase 3 trial of IVIg 10% launches
Disease control Recruiting nowThis study tests a medicine called KIg 10 (a type of IVIg) in 40 adults with chronic ITP, a condition where the immune system destroys platelets, causing bleeding and bruising. The goal is to see if KIg 10 can safely raise platelet counts and stop bleeding. Participants receive t…
Phase: PHASE3 • Sponsor: Kedrion S.p.A. • Aim: Disease control
Last updated May 06, 2026 16:02 UTC